Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership with the University of Michigan in the United States. Financial details of the collaboration remain undisclosed.
The partnership will focus on developing an innovative delivery system for glucagon-like peptide-1 (GLP-1) drug targets, with the University of Michigan tasked with the construction and development of this system. Clinical trials are set to take place in both China and the U.S. Future patent rights will be co-signed by both entities. Menovo will retain global commercial development rights for the technological advancements resulting from this collaboration, while the University of Michigan will assist with subsequent technological enhancements.- Flcube.com
